RFL - NYSE
Rafael Holdings, Inc.
$1.39
+7.0%Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
At a Glance
Live SnapshotRafael Holdings, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Rafael Holdings, Inc. Cash Flow Statement
RFL • NYSE
| Rafael Holdings, Inc. Cash Flow Statement | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 | Jul 2020 | Jul 2019 | Jul 2018 | Jul 2017 | Jul 2016 | Jul 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||
-30.6M | -65M | -2.2M | -140.5M | -22.8M | -10.4M | -4.9M | -12.1M | 138K | 710K | -467K | |
288K | 225K | 78K | 72K | 70K | 1.9M | 1.8M | 1.7M | 1.7M | 1.6M | 1.2M | |
-165K | 0.0 | 944K | 0.0 | 6K | 13K | -19K | 8.9M | -295K | 368K | 0.0 | |
2.1M | 2.3M | 2.2M | -917K | 0.0 | 0.0 | 372K | 0.0 | 0.0 | 0.0 | 0.0 | |
8.5M | 55.3M | -11.8M | 115.3M | 8.2M | 2.7M | -868K | 104K | 113K | 95K | -354K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (63K) | (24K) | (0.0) | |
967K | -610K | -92K | -10K | -989K | 1.2M | 1.6M | -792K | -3.2M | -2.7M | -953K | |
-18.9M | -7.8M | -10.9M | -26.1M | -15.6M | -4.7M | -3.1M | -1.8M | -1.6M | 72K | -571K | |
INVESTING ACTIVITIES | |||||||||||
-4K | -143K | (51.7M) | -2K | (0.0) | -534K | -399K | -710K | -1.8M | -1.6M | (0.0) | |
(0.0) | (2.4M) | -5.1M | (0.0) | (4.6M) | (0.0) | -55.9M | (864K) | (0.0) | (0.0) | (0.0) | |
-17M | -162.4M | -208.4M | -65.3M | -11.1M | -500K | (55.5M) | -151K | -9.4M | -2.1M | (0.0) | |
80.7M | 156.2M | 186.5M | 28.5M | 0.0 | 0.0 | 25M | 6.7M | 0.0 | 0.0 | 0.0 | |
-19.7M | -6.8M | -3.5M | -27M | -750K | 0.0 | -55.5M | -1.7M | -11.2M | -3.7M | -8.8M | |
(44M) | -10.8M | (21.2M) | -63.8M | -7.3M | -1M | -31.2M | (4.1M) | -11.2M | -3.7M | -8.8M | |
FINANCING ACTIVITIES | |||||||||||
25M | -168K | -218K | 110.2M | 15.1M | 29K | 7.8M | 0.0 | 0.0 | 0.0 | 0.0 | |
5K | -800K | 0.0 | 0.0 | 0.0 | 0.0 | 18.3M | 0.0 | 0.0 | -6.4M | 10M | |
(0.0) | -168K | -218K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-220K | 789K | -15M | -6.3M | 14.3M | -125K | 12.6M | 1.8M | 22.3M | 6.6M | 0.0 | |
24.8M | -179K | -15.2M | 103.9M | 29.4M | -96K | 30.9M | 1.8M | 22.3M | 265K | 10M | |
CASH FLOW SUMMARY | |||||||||||
153K | -22K | -146K | -306K | 122K | -22K | -298K | 3K | 0.0 | 3K | -95K | |
50.1M | -18.8M | -5M | 13.7M | 6.6M | -5.8M | -3.8M | 4M | 9.4M | -3.3M | 519K | |
2.7M | 21.5M | 26.5M | 12.9M | 6.2M | 12M | 15.8M | 11.8M | 2.3M | 5.7M | 5.1M | |
52.8M | 2.7M | 21.5M | 26.5M | 12.9M | 6.2M | 12M | 15.8M | 11.8M | 2.3M | 5.7M | |
-18.9M | -8M | 40.8M | -26.1M | -15.8M | -5.2M | -3.5M | -2.5M | -3.4M | -1.5M | -571K |
SEC Filings
RFL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | April 22, 2026 | April 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 16, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | March 16, 2026 | January 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 08, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | December 12, 2025 | October 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 11, 2025 | December 11, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 02, 2025 | December 02, 2025 | 2025 | |
DEF 14A DEF 14A 2026 N/A | November 18, 2025 | January 08, 2026 | 2026 | |
10-K 10-K 2025 FY FY | October 29, 2025 | July 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 29, 2025 | October 29, 2025 | 2025 |
Related Guides
Continue your RFL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.